新闻源 财富源

2019年10月21日 星期一

誉衡药业(002437)公告正文

誉衡药业:2016年第一季度报告全文

公告日期:2016-04-27

 哈尔滨誉衡药业股份有限公司



证券代码:002437                 证券简称:誉衡药业    公告编号:2016-083




                          哈尔滨誉衡药业股份有限公司

                              2016 年第一季度报告




                                 2016 年 04 月




                                       第1页
  哈尔滨誉衡药业股份有限公司




                                        第一节 重要提示

    公司董事会、监事会及董事、监事、高级管理人员保证季度报告内容的真实、准确、完整,不存在虚假记载、误导性陈
述或者重大遗漏,并承担个别和连带的法律责任。

    所有董事均已出席了审议本次季报的董事会会议。

    公司负责人朱吉满、主管会计工作负责人刁秀强及会计机构负责人(会计主管人员)程朝阳声明:保证季度报告中财务报
表的真实、准确、完整。




                                                   第2页
  哈尔滨誉衡药业股份有限公司




                            第二节 主要财务数据及股东变化

一、主要会计数据和财务指标

公司是否因会计政策变更及会计差错更正等追溯调整或重述以前年度会计数据
□ 是 √ 否

                                            本报告期                 上年同期               本报告期比上年同期增减

营业收入(元)                                  596,972,998.24          527,590,963.41                         13.15%

归属于上市公司股东的净利润(元)                152,706,647.34          125,263,214.46                         21.91%

归属于上市公司股东的扣除非经常性损
                                                135,971,231.12          114,471,137.71                         18.78%
益的净利润(元)

经营活动产生的现金流量净额(元)                -12,427,346.00           66,492,535.02                        -118.69%

基本每股收益(元/股)                                     0.21                       0.17                      23.53%

稀释每股收益(元/股)                                     0.21                       0.17                      23.53%

加权平均净资产收益率                                     4.37%                    4.06%                         0.31%

                                                                                            本报告期末比上年度末增
                                           本报告期末                上年度末
                                                                                                         减

总资产(元)                                  8,149,002,066.68         8,312,681,074.32                        -1.97%

归属于上市公司股东的净资产(元)              3,568,027,970.93         3,415,321,704.49                         4.47%

非经常性损益项目和金额
√ 适用 □ 不适用
                                                                                                              单位:元

                         项目                              年初至报告期期末金额                   说明

非流动资产处置损益(包括已计提资产减值准备的冲销部分)                   32,089.43

计入当期损益的政府补助(与企业业务密切相关,按照国家统                               其中,拉萨市曲水县政府企业发
                                                                     16,117,593.52
一标准定额或定量享受的政府补助除外)                                                 展基金 1469.68 万元

除同公司正常经营业务相关的有效套期保值业务外,持有交易
性金融资产、交易性金融负债产生的公允价值变动损益,以及
                                                                      2,293,666.25 银行理财收益
处置交易性金融资产、交易性金融负债和可供出售金融资产取
得的投资收益

其他符合非经常性损益定义的损益项目                                      465,613.93

减:所得税影响额                                                      2,010,008.82

     少数股东权益影响额(税后)                                         163,538.09

合计                                                                 16,735,416.22                  --

对公司根据《公开发行证券的公司信息披露解释性公告第 1 号——非经常性损益》定义界定的非经常性损益项目,以及把《公
开发行证券的公司信息披露解释性公告第 1 号——非经常性损益》中列举的非经常性损益项目界定为经常性损益的项目,应

                                                    第3页
  哈尔滨誉衡药业股份有限公司


说明原因
□ 适用 √ 不适用
公司报告期不存在将根据《公开发行证券的公司信息披露解释性公告第 1 号——非经常性损益》定义、列举的非经常性损益
项目界定为经常性损益的项目的情形。


二、报告期末股东总数及前十名股东持股情况表

1、普通股股东和表决权恢复的优先股股东数量及前 10 名股东持股情况表

                                                                                                               单位:股

                                                               报告期末表决权恢复的优先
报告期末普通股股东总数                                31,192                                                         0
                                                               股股东总数(如有)
                                                前 10 名股东持股情况
                                                                                 持有有限售条      质押或冻结情况
             股东名称                     股东性质     持股比例     持股数量
                                                                                 件的股份数量 股份状态        数量
哈尔滨恒世达昌科技有限公司         境内非国有法人         42.63% 312,375,000                0 质押          277,710,000
YU HENG INTERNATIONAL
                                   境外法人               19.54% 143,192,968                0 质押           35,500,000
INVESTMENTS CORPORATION
ORIENTAL KEYSTONE
                                   境外法人                1.95%    14,301,533              0
INVESTMENT LIMITED
中融国际信托有限公司-中融-日进
斗金 1 号结构化证券投资集合资金信 其他                     1.09%     7,998,370              0
托计划
杨红冰                             境内自然人              0.89%     6,535,000       4,901,250
中国农业银行股份有限公司-宝盈转
                                   其他                    0.77%     5,610,416              0
型动力灵活配置混合型证券投资基金
中央汇金资产管理有限责任公司       国有法人                0.72%     5,255,900              0
尹美娟                             境内自然人              0.59%     4,325,956              0
韦秀萍                             境内自然人              0.47%     3,446,817              0
朱吉满                             境内自然人              0.45%     3,322,500       3,322,500
                                          前 10 名无限售条件股东持股情况
                                                                                                 股份种类
                        股东名称                        持有无限售条件股份数量
                                                                                        股份种类            数量
哈尔滨恒世达昌科技有限公司                                              312,375,000 人民币普通股            312,375,000
YU HENG INTERNATIONAL INVESTMENTS
                                                                        143,192,968 人民币普通股            143,192,968
CORPORATION
ORIENTAL KEYSTONE INVESTMENT LIMITED                                     14,301,533 人民币普通股             14,301,533
中融国际信托有限公司-中融-日进斗金 1 号结构化证券
                                                                          7,998,370 人民币普通股              7,998,370
投资集合资金信托计划
中国农业银行股份有限公司-宝盈转型动力灵活配置混
                                                                          5,610,416 人民币普通股              5,610,416
合型证券投资基金
中央汇金资产管理有限责任公司                                              5,255,900 人民币普通股              5,255,900
尹美娟                                                                    4,325,956 人民币普通股              4,325,956


                                                       第4页
  哈尔滨誉衡药业股份有限公司


韦秀萍                                                                    3,446,817 人民币普通股      3,446,817
尹江                                                                      3,187,130 人民币普通股      3,187,130
宋晓文                                                                    2,832,372 人民币普通股      2,832,372
                                                     1、恒世达昌、YU HENG INTERNATIONAL INVESTMENTS
                                                     CORPORATION 以及 ORIENTAL KEYSTONE INVESTMENT
                                                     LIMITED 由同一实际控制人朱吉满控制。
                                                     2、实际控制人朱吉满通过《中融国际信托有限公司-中融-日
上述股东关联关系或一致行动的说明
                                                     进斗金 1 号结构化证券投资集合资金信托计划》持有公司
                                                     7,998,370 股股票。
                                                     3、未知其他股东是否存在关联关系,也未知是否属于《上市公
                                                     司收购管理办法》中规定的一致行动人。
                                                     1、尹美娟通过融资融券业务持有公司股票 4,302,256 股。
前 10 名普通股股东参与融资融券业务情况说明(如有)
                                                     2、韦秀萍通过融资融券业务持有公司股票 3,446,817 股。

公司前 10 名普通股股东、前 10 名无限售条件普通股股东在报告期内是否进行约定购回交易
□ 是 √ 否
公司前 10 名普通股股东、前 10 名无限售条件普通股股东在报告期内未进行约定购回交易。


2、公司优先股股东总数及前 10 名优先股股东持股情况表

□ 适用 √ 不适用




                                                     第5页
  哈尔滨誉衡药业股份有限公司



                                             第三节 重要事项

一、报告期主要会计报表项目、财务指标发生变动的情况及原因

√ 适用 □ 不适用

1、2016年3月31日资产负债表项目
           项目             期末余额          期初余额       变动率                          原因说明
货币资金                   735,937,767.64   1,193,363,406.18 -38.33% 主要系本期支付股权收购尾款及新增投资业务所致
预付款项                   200,759,337.12     118,939,646.04 68.79% 主要系本期代理品种的预付货款增加所致
应收利息                      541,510.67          205,402.28 163.63% 主要系本期应收定期存款利息增加所致
                                                                        系本期增加对上海赛领博达科尔投资合伙企业的注
可供出售金融资产           138,391,436.80      25,273,136.80 447.58%
                                                                        资及对海外投资基金(毓承资本)的第二笔投资
                                                                        主要系上年开具的大额银行承兑票据在本期到期解
应付票据                    27,330,603.57      91,870,932.61 -70.25%
                                                                        付所致
应交税费                    46,906,883.24      86,126,735.86 -45.54% 主要系本期增值税、所得税等相关税费的缴纳所致
应付利息                     4,173,840.24       2,619,305.56 59.35% 主要系本期应支付的借款利息增加
应付股利                     1,893,210.00      11,393,210.00 -83.38% 主要系本期蒲公英股东现金分红款的支付所致
                                                                        系逐步优化长短期借款的配置,增加2年期银行借款
长期借款                   800,000,000.00     300,000,000.00 166.67%
                                                                        所致

库存股                       2,200,900.08       4,328,082.48 -49.15% 系本期完成7名离职人员的限制性股票注销

2、2016年1-3月利润表项目
           项目            本期发生额        上期发生额      变动率                          原因说明
销售费用                    52,036,098.49      80,244,635.06 -35.15% 主要系本期销售模式的调整,市场费用进一步降低
                                                                        主要系本期研发费用、人力资源费用、日常运营费用、
管理费用                   119,079,384.73      85,948,677.53 38.55%
                                                                        折旧摊销费用等增长
财务费用                    24,469,782.22      14,473,920.18 69.06% 主要系本期银行借款增加导致利息支出增加
资产减值损失                  455,171.97         -646,687.69 170.39% 主要系本期按账龄分析法计提的坏账准备增加所致
投资收益                     2,293,666.25       1,733,201.16 32.34% 主要系本期银行理财收益的增加所致
营业外收入                  16,874,791.62      12,164,177.90 38.73% 主要系本期政府补助项目增加所致
少数股东损益                  862,365.02        4,404,348.40 -80.42% 主要系公司完成收购普德药业、上海华拓少数股东股
                                                                        权所致
3、2016年1-3月现金流量表项目
           项目            本期发生额        上期发生额      变动率                          原因说明
经营活动产生的现金流                                                    主要系本期预付款业务增加、库存大量备货以及票据
                           -12,427,346.00      66,492,535.02 -118.69%
量净额                                                                  到期解付等导致,二季度情况将会好转
投资活动产生的现金流                                                    主要系上期支付普德药业等股权收购尾款较大,本期
                       -611,669,305.99      -1,254,376,756.27 -51.24%
量净额                                                                  支付股权收购尾款相对减少
筹资活动产生的现金流
                           281,267,379.57     596,182,772.77 -52.82% 主要系本期偿还银行借款较多所致
量净额



                                                          第6页
  哈尔滨誉衡药业股份有限公司


二、重要事项进展情况及其影响和解决方案的分析说明

√ 适用 □ 不适用
    1、重要事项
             重要事项概述                     披露日期                           临时报告披露网站查询索引
                                                                详见发布在《中国证券报》、《证券时报》及巨潮资讯网
公司主动撤回银杏内酯 B 注射液的注册
                                          2016 年 01 月 04 日 www.cninfo.com.cn(以下简称“指定披露媒体”)的 2016-001
申请
                                                                号公告《关于全资子公司撤回药品注册申请的提示性公告》。
                                                                详见发布在指定披露媒体的 2015-136 号《非公开发行股票预
                                          2015 年 10 月 27 日
                                                                案》等公告。
                                                                详见发布在指定披露媒体的 2015-177 号公告《关于非公开发行
                                          2015 年 12 月 09 日
                                                                股票申请获得中国证监会受理的公告》。
公司非公开发行股票获中国证监会受
                                                                详见发布在指定披露媒体的 2016-003 号公告《关于收到<中国
理,公司根据中国证监会的反馈意见调 2016 年 01 月 14 日
                                                                证监会行政许可项目审查反馈意见通知书>的公告》。
整非公开发行方案并补充相关资料
                                                                详见发布在指定披露媒体的 2016-023 号《非公开发行 A 股股
                                          2016 年 03 月 05 日
                                                                票预案(修订稿)》等公告。
                                                                详见发布在指定披露媒体的 2016-043 号《非公开发行 A 股股
                                          2016 年 03 月 23 日
                                                                票预案(二次修订稿)》等公告。
公司完成 7 名离职人员已授予尚未解锁                             详见发布在指定披露媒体的 2016-004 号公告《关于部分已授予
                                          2016 年 01 月 28 日
的限制性股票的回购注销,并完成工商                              但尚未解锁的限制性股票回购注销完成的公告》。
登记的变更,公司总股本由 73,300.95 万                           详见发布在指定披露媒体的 2016-048 号公告《关于完成注册资
                                          2016 年 03 月 31 日
股减至 73,280.745 万股                                          本工商变更登记的公告》。
公司下属公司誉衡基因生物科技(深圳)                    详见发布在指定披露媒体的 2016-006 号公告《关于收购上海仁
                                    2016 年 02 月 02 日
有限公司以 1,000 万元人民币收购上海                     东医学检验所有限公司 100%股权并进行后续增资的公告》。
仁东医学检验所有限公司 100%股权并                               详见发布在指定披露媒体的 2016-017 号公告《关于下属公司收
                                          2016 年 03 月 04 日
完成工商变更登记                                                购上海仁东医学检验所有限公司 100%股权的进展公告》。
公司预披露 2015 年利润分配及资本公积                            详见发布在指定披露媒体的 2016-009 号公告《关于 2015 年年
                                          2016 年 02 月 04 日
金转增股本预案                                                  度利润分配及资本公积金转增股本预案的预披露公告》。
公司通过全资子公司誉衡(香港)有限
公司出资 2,500 万美元认购 Proteus
Digital Health, Inc 发行的 H 轮优先股;
                                                                详见发布在指定披露媒体的 2016-012 号公告《关于认购 Proteus
同时,通过 H 轮优先股的领投人上海赛 2016 年 02 月 23 日
                                                                Digital Health, Inc 优先股的公告》。
领博达科尔投资合伙企业(有限合伙)
间接出资 1,500 万美元,认购 Proteus 公
司发行的 H 轮优先股
                                                                详见发布在指定披露媒体的 2016-013 号公告《关于投资设立上
上海誉瀚股权投资基金合伙企业(有限 2016 年 02 月 27 日
                                                                海誉瀚股权投资基金合伙企业(有限合伙)的进展公告》。
合伙)及上海赛领博达科尔投资合伙企
                                                                详见发布在指定披露媒体的 2016-014 号公告《关于投资设立上
业(有限合伙)完成工商登记                2016 年 02 月 27 日
                                                                海赛领博达科尔投资合伙企业(有限合伙)的进展公告》。
控股子公司哈尔滨蒲公英药业有限公司                              详见发布在指定披露媒体的 2016-035 号公告《关于控股子公司
                                          2016 年 03 月 11 日
获得 GMP 证书                                                   获得 GMP 证书的公告》。
    2、报告期内其他重要事项
    公司化药3.1类注射用米铂、化药3.2类奥氮平氟西汀胶囊、化药3.1类注射用左亚叶酸、原化药3.3类吸入用盐酸氨溴索等
多个品种获得药物临床试验批件。

                                                           第7页
  哈尔滨誉衡药业股份有限公司


    3、期后事项
              期后事项概述                   披露日期                    临时报告披露网站查询索引
公司及全资子公司宁波誉衡健康投资有
限公司与江苏京东邦能投资管理有限公
                                                         详见发布在指定披露媒体的2016-052号公告《关于与江苏京东
司共同出资设立公司誉衡京东健康投资 2016年04月12日
                                                         邦能投资管理有限公司共同出资设立公司的公告》。
管理有限公司(以工商行政管理部门最
终核定名称为准)
注销全资子公司哈尔滨吉尔生物科技有                       详见发布在指定披露媒体的2016-053号公告《关于注销全资子
                                       2016年04月12日
限公司                                                   公司哈尔滨吉尔生物科技有限公司的公告》。
普德药业重大资产重组完成股权过户,
                                                         详见发布在指定披露媒体的2016-056号公告《关于重大资产重
并取得新的《营业执照》,普德药业成 2016年04月14日
                                                         组标的资产完成股权过户的公告》。
为公司全资子公司


三、公司、股东、实际控制人、收购人、董事、监事、高级管理人员或其他关联方在报告期
内履行完毕及截至报告期末尚未履行完毕的承诺事项

√ 适用 □ 不适用

         承诺事由       承诺方    承诺类型                  承诺内容                    承诺时间 承诺期限 履行情况
                                             承诺其持有权益达 50%以上或实际控制的企
                                             业或单位("附属公司")目前并没有直接或间
                                             接地从事任何与公司实际从事的业务发生利
                                  关于同业 益冲突或在市场、资源、地域方面存在竞争
                                  竞争、关 的任何业务活动。其及其附属公司在今后的
                                  联交易、 任何时间不会直接或间接地以任何方式(包括 2010 年 06             正常履行
                       恒世达昌                                                                 长期
                                  资金占用 但不限于自营、合资或联营)参与或进行与公 月 23 日               中
                                  方面的承 司实际从事的业务存在直接或间接竞争的任
                                  诺         何业务活动(与公司合作开发除外)。凡其及其
                                             附属公司有任何商业机会可从事、参与或入
                                             股任何可能会与公司生产经营构成竞争的业
                                             务,会将上述商业机会优先让予公司。
首次公开发行或再融                           承诺其及其实际控制的企业或单位("附属公
资时所作承诺                                 司")目前并没有直接或间接地从事任何与公
                                             司实际从事的业务发生利益冲突或在市场、
                                  关于同业 资源、地域方面存在竞争的任何业务活动。
                                  竞争、关 其及其附属公司在今后的任何时间不会直接
                       朱吉满、 联交易、 或间接地以任何方式(包括但不限于自营、合 2010 年 06               正常履行
                                                                                                长期
                       白莉惠     资金占用 资或联营)参与或进行与公司实际从事的业务 月 23 日               中
                                  方面的承 存在直接或间接竞争的任何业务活动(与公司
                                  诺         合作开发除外)。其及其附属公司有任何商业
                                             机会可从事、参与或入股任何可能会与公司
                                             生产经营构成竞争的业务,会将上述商业机
                                             会优先让予公司。
                       朱吉满、 股份限售 限售期届满后,在担任公司董事、监事或高 2010 年 06                正常履行
                                                                                                长期
                       白莉惠、 承诺         管人员期间,每年转让的股份不超过所间接 月 23 日              中

                                                        第8页
  哈尔滨誉衡药业股份有限公司


                       王东绪、              持有公司股份总数的 25%;离职后半年内,
                       杨红冰                不转让所间接持有的公司股份。
                                             限制性股票激励计划授予对象朱吉满先生承
                                  股份限售                                            2014 年 10             正常履行
股权激励承诺           朱吉满                诺所获股票自授予日起三十六个月内不得转                36 个月
                                  承诺                                                月 31 日               中
                                             让。
承诺是否按时履行       是
如承诺超期未履行完
毕的,应当详细说明未
                       不适用
完成履行的具体原因
及下一步的工作计划


四、对 2016 年 1-6 月经营业绩的预计

2016 年 1-6 月预计的经营业绩情况:归属于上市公司股东的净利润为正值且不属于扭亏为盈的情形
归属于上市公司股东的净利润为正值且不属于扭亏为盈的情形

2016 年 1-6 月归属于上市公司股东的净利润变动幅度                                5.00% 至                       25.00%

2016 年 1-6 月归属于上市公司股东的净利润变动区间(万元)                      33,987.94 至                   40,461.84

2015 年 1-6 月归属于上市公司股东的净利润(万元)                                                             32,369.47

业绩变动的原因说明                                             夯实现有业务,实现平稳增长。


五、以公允价值计量的金融资产

□ 适用 √ 不适用


六、违规对外担保情况

□ 适用 √ 不适用
公司报告期无违规对外担保情况。


七、控股股东及其关联方对上市公司的非经营性占用资金情况

□ 适用 √ 不适用
公司报告期不存在控股股东及其关联方对上市公司的非经营性占用资金。


八、报告期内接待调研、沟通、采访等活动登记表

□ 适用 √ 不适用
公司报告期内未发生接待调研、沟通、采访等活动。




                                                       第9页
  哈尔滨誉衡药业股份有限公司




                                       第四节 财务报表

一、财务报表

1、合并资产负债表

编制单位:哈尔滨誉衡药业股份有限公司
                                         2016 年 03 月 31 日
                                                                                            单位:元

                   项目                       期末余额                   期初余额
流动资产:
    货币资金                                          735,937,767.64                1,193,363,406.18
    结算备付金
    拆出资金
    以公允价值计量且其变动计入当期损
益的金融资产
    衍生金融资产
    应收票据                                             38,025,617.79                37,860,195.21
    应收账款                                             91,512,653.68                97,725,677.96
    预付款项                                          200,759,337.12                 118,939,646.04
    应收保费
    应收分保账款
    应收分保合同准备金
    应收利息                                               541,510.67                    205,402.28
    应收股利
    其他应收款                                        299,834,869.59                 288,820,335.42
    买入返售金融资产
    存货                                              310,211,927.07                 272,364,591.19
    划分为持有待售的资产
    一年内到期的非流动资产                                8,394,584.50                  7,764,857.22
    其他流动资产                                         36,488,475.94                40,789,464.54
流动资产合计                                        1,721,706,744.00                2,057,833,576.04
非流动资产:
    发放贷款及垫款
    可供出售金融资产                                  138,391,436.80                  25,273,136.80
    持有至到期投资
    长期应收款
    长期股权投资                                      129,405,380.72                 129,405,380.72
    投资性房地产
    固定资产                                        1,579,477,595.37                1,540,501,564.12
    在建工程                                          112,803,557.92                 104,447,512.91


                                              第 10 页
 哈尔滨誉衡药业股份有限公司


    工程物资
    固定资产清理
    生产性生物资产
    油气资产
    无形资产                                  448,986,996.48       431,244,226.33
    开发支出                                      51,642,525.64     51,037,801.12
    商誉                                     3,638,771,979.19     3,623,156,883.80
    长期待摊费用                                  23,136,663.29     19,723,057.78
    递延所得税资产                                25,571,439.93     24,387,914.63
    其他非流动资产                            279,107,747.34       305,670,020.07
非流动资产合计                               6,427,295,322.68     6,254,847,498.28
资产总计                                     8,149,002,066.68     8,312,681,074.32
流动负债:
    短期借款                                 1,400,000,000.00     1,699,000,000.00
    向中央银行借款
    吸收存款及同业存放
    拆入资金
    以公允价值计量且其变动计入当期损
益的金融负债
    衍生金融负债
    应付票据                                      27,330,603.57     91,870,932.61
    应付账款                                      96,090,389.15     95,480,858.12
    预收款项                                  152,248,066.57       125,586,975.81
    卖出回购金融资产款
    应付手续费及佣金
    应付职工薪酬                                   6,144,576.70       7,227,946.40
    应交税费                                      46,906,883.24     86,126,735.86
    应付利息                                       4,173,840.24       2,619,305.56
    应付股利                                       1,893,210.00     11,393,210.00
    其他应付款                                216,863,624.55       246,513,163.58
    应付分保账款
    保险合同准备金
    代理买卖证券款
    代理承销证券款
    划分为持有待售的负债
    一年内到期的非流动负债                   1,350,224,420.96     1,618,630,463.16
    其他流动负债
流动负债合计                                 3,301,875,614.98     3,984,449,591.10
非流动负债:
    长期借款                                  800,000,000.00       300,000,000.00
    应付债券
      其中:优先股
               永续债


                                       第 11 页
  哈尔滨誉衡药业股份有限公司


    长期应付款                                          321,401,063.61                  456,548,563.61
    长期应付职工薪酬
    专项应付款                                               1,953,116.56                  1,953,568.23
    预计负债
    递延收益                                                37,892,692.31                39,042,699.50
    递延所得税负债                                          32,582,781.69                33,277,485.92
    其他非流动负债                                          14,733,000.40                12,414,000.30
非流动负债合计                                         1,208,562,654.57                 843,236,317.56
负债合计                                               4,510,438,269.55                4,827,685,908.66
所有者权益:
    股本                                                732,807,450.00                  733,009,500.00
    其他权益工具
      其中:优先股
               永续债
    资本公积                                           1,061,866,201.33                1,063,791,333.73
    减:库存股                                               2,200,900.08                  4,328,082.48
    其他综合收益
    专项储备
    盈余公积                                            147,520,681.77                  147,520,681.77
    一般风险准备
    未分配利润                                         1,628,034,537.91                1,475,328,271.47
归属于母公司所有者权益合计                             3,568,027,970.93                3,415,321,704.49
    少数股东权益                                            70,535,826.20                69,673,461.17
所有者权益合计                                         3,638,563,797.13                3,484,995,165.66
负债和所有者权益总计                                   8,149,002,066.68                8,312,681,074.32

法定代表人:朱吉满                     主管会计工作负责人:刁秀强           会计机构负责人:程朝阳


2、母公司资产负债表

                                                                                               单位:元

                   项目                         期末余额                    期初余额
流动资产:
    货币资金                                            308,675,357.91                  301,982,833.79
    以公允价值计量且其变动计入当期损
益的金融资产
    衍生金融资产
    应收票据                                                 5,432,420.00                  8,025,188.18
    应收账款                                                29,795,178.60                43,467,657.22
    预付款项                                                23,636,732.05                17,271,662.64
    应收利息                                                  466,986.67                     45,253.28
    应收股利                                            281,086,006.06                   88,500,000.00
    其他应收款                                          992,837,250.83                  805,611,531.56
    存货                                                    40,120,143.51                32,126,139.34


                                                 第 12 页
 哈尔滨誉衡药业股份有限公司


    划分为持有待售的资产
    一年内到期的非流动资产                         1,907,290.90        740,996.47
    其他流动资产                                  11,837,520.85       5,196,193.09
流动资产合计                                 1,695,794,887.38     1,302,967,455.57
非流动资产:
    可供出售金融资产                          115,340,796.80        11,300,796.80
    持有至到期投资
    长期应收款
    长期股权投资                             5,421,802,235.40     5,415,209,535.40
    投资性房地产
    固定资产                                  458,573,801.55       465,385,169.81
    在建工程                                      12,694,657.40     16,185,606.56
    工程物资
    固定资产清理
    生产性生物资产
    油气资产
    无形资产                                      99,963,157.08     76,502,733.02
    开发支出                                      12,356,132.08     12,356,132.08
    商誉
    长期待摊费用                                   6,388,968.54       1,981,437.85
    递延所得税资产                                 1,102,477.11       1,102,477.11
    其他非流动资产                            157,464,973.38       165,710,232.48
非流动资产合计                               6,285,687,199.34     6,165,734,121.11
资产总计                                     7,981,482,086.72     7,468,701,576.68
流动负债:
    短期借款                                  700,000,000.00      1,100,000,000.00
    以公允价值计量且其变动计入当期损
益的金融负债
    衍生金融负债
    应付票据
    应付账款                                      29,358,081.23     33,970,040.05
    预收款项                                      30,092,132.38     26,228,006.53
    应付职工薪酬                                    120,405.10         146,293.26
    应交税费                                       6,922,274.12     22,344,819.89
    应付利息                                       3,429,361.07       2,046,763.89
    应付股利                                       1,893,210.00       1,893,210.00
    其他应付款                               1,367,276,768.03      852,170,151.35
    划分为持有待售的负债
    一年内到期的非流动负债                   1,295,076,920.96     1,495,076,920.96
    其他流动负债
流动负债合计                                 3,434,169,152.89     3,533,876,205.93
非流动负债:
    长期借款                                  800,000,000.00       300,000,000.00


                                       第 13 页
  哈尔滨誉衡药业股份有限公司


    应付债券
      其中:优先股
               永续债
    长期应付款                                       321,401,063.61                    401,401,063.61
    长期应付职工薪酬
    专项应付款
    预计负债
    递延收益                                             10,026,083.38                  10,387,833.37
    递延所得税负债
    其他非流动负债
非流动负债合计                                      1,131,427,146.99                   711,788,896.98
负债合计                                            4,565,596,299.88               4,245,665,102.91
所有者权益:
    股本                                             732,807,450.00                    733,009,500.00
    其他权益工具
      其中:优先股
               永续债
    资本公积                                        1,426,528,925.08               1,428,454,057.48
    减:库存股                                            2,200,900.08                   4,328,082.48
    其他综合收益
    专项储备
    盈余公积                                         147,520,681.77                    147,520,681.77
    未分配利润                                      1,111,229,630.07                   918,380,317.00
所有者权益合计                                      3,415,885,786.84               3,223,036,473.77
负债和所有者权益总计                                7,981,482,086.72               7,468,701,576.68

法定代表人:朱吉满                  主管会计工作负责人:刁秀强            会计机构负责人:程朝阳


3、合并利润表

                                                                                             单位:元

                    项目                    本期发生额                    上期发生额
一、营业总收入                                           596,972,998.24                527,590,963.41
    其中:营业收入                                       596,972,998.24                527,590,963.41
           利息收入
           已赚保费
           手续费及佣金收入
二、营业总成本                                           439,477,343.50                381,526,056.70
    其中:营业成本                                       238,399,628.71                194,494,115.35
           利息支出
           手续费及佣金支出
           退保金
           赔付支出净额
           提取保险合同准备金净额


                                              第 14 页
 哈尔滨誉衡药业股份有限公司


             保单红利支出
             分保费用
             营业税金及附加                              5,037,277.38     7,011,396.27
             销售费用                                   52,036,098.49    80,244,635.06
             管理费用                                  119,079,384.73    85,948,677.53
             财务费用                                   24,469,782.22    14,473,920.18
             资产减值损失                                 455,171.97       -646,687.69
    加:公允价值变动收益(损失以“-”
号填列)
           投资收益(损失以“-”号填列)                2,293,666.25     1,733,201.16
           其中:对联营企业和合营企业的投
资收益
           汇兑收益(损失以“-”号填列)
三、营业利润(亏损以“-”号填列)                     159,789,320.99   147,798,107.87
    加:营业外收入                                      16,874,791.62    12,164,177.90
           其中:非流动资产处置利得
    减:营业外支出                                         116,840.27        89,893.39
           其中:非流动资产处置损失
四、利润总额(亏损总额以“-”号填列)                 176,547,272.34   159,872,392.38
    减:所得税费用                                      22,978,259.98    30,204,829.52
五、净利润(净亏损以“-”号填列)                     153,569,012.36   129,667,562.86
    归属于母公司所有者的净利润                         152,706,647.34   125,263,214.46
    少数股东损益                                          862,365.02      4,404,348.40
六、其他综合收益的税后净额
  归属母公司所有者的其他综合收益的税
后净额
   (一)以后不能重分类进损益的其他综
合收益
         1.重新计量设定受益计划净负债或
净资产的变动
         2.权益法下在被投资单位不能重分
类进损益的其他综合收益中享有的份额
   (二)以后将重分类进损益的其他综合
收益
         1.权益法下在被投资单位以后将重
分类进损益的其他综合收益中享有的份额
         2.可供出售金融资产公允价值变动
损益
         3.持有至到期投资重分类为可供出
售金融资产损益
         4.现金流量套期损益的有效部分
         5.外币财务报表折算差额
         6.其他


                                            第 15 页
  哈尔滨誉衡药业股份有限公司


  归属于少数股东的其他综合收益的税后
净额
七、综合收益总额                                                 153,569,012.36                  129,667,562.86
    归属于母公司所有者的综合收益总额                             152,706,647.34                  125,263,214.46
    归属于少数股东的综合收益总额                                    862,365.02                     4,404,348.40
八、每股收益:
    (一)基本每股收益                                                     0.21                            0.17
    (二)稀释每股收益                                                     0.21                            0.17

本期发生同一控制下企业合并的,被合并方在合并前实现的净利润为:0.00 元,上期被合并方实现的净利润为:0.00 元。
法定代表人:朱吉满                          主管会计工作负责人:刁秀强              会计机构负责人:程朝阳


4、母公司利润表

                                                                                                       单位:元

                      项目                          本期发生额                      上期发生额
一、营业收入                                                     88,763,259.52                   111,706,722.22
    减:营业成本                                                 22,342,412.27                    32,785,298.64
           营业税金及附加                                         1,245,552.03                     1,357,558.75
           销售费用                                              16,611,596.39                    31,458,824.87
           管理费用                                              67,524,628.91                    33,810,988.88
           财务费用                                              18,021,305.77                    12,773,878.03
           资产减值损失                                             308,921.73                      -204,414.06
    加:公允价值变动收益(损失以“-”
号填列)
           投资收益(损失以“-”号填列)                    222,575,890.32                      234,271,843.52
           其中:对联营企业和合营企业的投
资收益
二、营业利润(亏损以“-”号填列)                           185,284,732.74                      233,996,430.63
    加:营业外收入                                                  382,567.57                     2,451,177.70
           其中:非流动资产处置利得
    减:营业外支出                                                        0.04                        16,162.62
           其中:非流动资产处置损失
三、利润总额(亏损总额以“-”号填列)                       185,667,300.27                      236,431,445.71
    减:所得税费用                                                -7,182,012.80                    1,258,813.19
四、净利润(净亏损以“-”号填列)                           192,849,313.07                      235,172,632.52
五、其他综合收益的税后净额
   (一)以后不能重分类进损益的其他综
合收益
         1.重新计量设定受益计划净负债或
净资产的变动
         2.权益法下在被投资单位不能重分
类进损益的其他综合收益中享有的份额
   (二)以后将重分类进损益的其他综合


                                                      第 16 页
  哈尔滨誉衡药业股份有限公司


收益
       1.权益法下在被投资单位以后将重
分类进损益的其他综合收益中享有的份额
       2.可供出售金融资产公允价值变动
损益
       3.持有至到期投资重分类为可供出
售金融资产损益
       4.现金流量套期损益的有效部分
       5.外币财务报表折算差额
       6.其他
六、综合收益总额                                         192,849,313.07                 235,172,632.52
七、每股收益:
    (一)基本每股收益                                              0.26                          0.32
    (二)稀释每股收益                                              0.26                          0.32

法定代表人:朱吉满                      主管会计工作负责人:刁秀强         会计机构负责人:程朝阳


5、合并现金流量表

                                                                                              单位:元

                   项目                         本期发生额                 上期发生额
一、经营活动产生的现金流量:
    销售商品、提供劳务收到的现金                        686,577,681.91                  568,837,996.88
    客户存款和同业存放款项净增加额
    向中央银行借款净增加额
    向其他金融机构拆入资金净增加额
    收到原保险合同保费取得的现金
    收到再保险业务现金净额
    保户储金及投资款净增加额
    处置以公允价值计量且其变动计入当
期损益的金融资产净增加额
    收取利息、手续费及佣金的现金
    拆入资金净增加额
    回购业务资金净增加额
    收到的税费返还                                           269,944.41
    收到其他与经营活动有关的现金                        133,407,154.54                  248,251,840.65
经营活动现金流入小计                                    820,254,780.86                  817,089,837.53
    购买商品、接受劳务支付的现金                        344,711,001.17                  194,532,766.88
    客户贷款及垫款净增加额
    存放中央银行和同业款项净增加额
    支付原保险合同赔付款项的现金
    支付利息、手续费及佣金的现金
    支付保单红利的现金
    支付给职工以及为职工支付的现金                       91,175,425.81                   71,834,322.32


                                                  第 17 页
  哈尔滨誉衡药业股份有限公司


    支付的各项税费                                       123,956,853.18                114,324,591.88
    支付其他与经营活动有关的现金                         272,838,846.70                369,905,621.43
经营活动现金流出小计                                     832,682,126.86                750,597,302.51
经营活动产生的现金流量净额                               -12,427,346.00                 66,492,535.02
二、投资活动产生的现金流量:
    收回投资收到的现金                                 2,039,294,824.26              1,170,010,000.00
    取得投资收益收到的现金                                    2,269,916.25               1,733,201.16
    处置固定资产、无形资产和其他长期资
                                                                47,300.00                  110,500.00
产收回的现金净额
    处置子公司及其他营业单位收到的现
金净额
    收到其他与投资活动有关的现金
投资活动现金流入小计                                   2,041,612,040.51              1,171,853,701.16
    购建固定资产、无形资产和其他长期资
                                                          36,424,525.01                 41,278,595.91
产支付的现金
    投资支付的现金                                     2,048,373,124.26              1,170,010,000.00
    质押贷款净增加额
    取得子公司及其他营业单位支付的现
                                                         568,483,697.23              1,014,101,861.52
金净额
    支付其他与投资活动有关的现金                                                       200,840,000.00
投资活动现金流出小计                                   2,653,281,346.50              2,426,230,457.43
投资活动产生的现金流量净额                              -611,669,305.99              -1,254,376,756.27
三、筹资活动产生的现金流量:
    吸收投资收到的现金
    其中:子公司吸收少数股东投资收到的
现金
    取得借款收到的现金                                   950,000,000.00              1,100,000,000.00
    发行债券收到的现金
    收到其他与筹资活动有关的现金                         114,596,365.81
筹资活动现金流入小计                                   1,064,596,365.81              1,100,000,000.00
    偿还债务支付的现金                                   749,000,000.00                480,000,000.00
    分配股利、利润或偿付利息支付的现金                    34,328,986.24                 23,791,747.23
    其中:子公司支付给少数股东的股利、
利润
    支付其他与筹资活动有关的现金                                                            25,480.00
筹资活动现金流出小计                                     783,328,986.24                503,817,227.23
筹资活动产生的现金流量净额                               281,267,379.57                596,182,772.77
四、汇率变动对现金及现金等价物的影响                                 -0.31
五、现金及现金等价物净增加额                            -342,829,272.73               -591,701,448.48
    加:期初现金及现金等价物余额                       1,017,919,279.57              1,071,101,367.31
六、期末现金及现金等价物余额                             675,090,006.84                479,399,918.83

法定代表人:朱吉满                       主管会计工作负责人:刁秀强          会计机构负责人:程朝阳




                                                   第 18 页
 哈尔滨誉衡药业股份有限公司


6、母公司现金流量表

                                                                                        单位:元

                   项目                  本期发生额                 上期发生额
一、经营活动产生的现金流量:
    销售商品、提供劳务收到的现金                121,533,196.08                   124,639,928.86
    收到的税费返还                                     23,913.12
    收到其他与经营活动有关的现金               1,124,409,580.65                  729,868,322.84
经营活动现金流入小计                           1,245,966,689.85                  854,508,251.70
    购买商品、接受劳务支付的现金                 35,117,257.32                    24,573,221.90
    支付给职工以及为职工支付的现金               33,755,425.23                    15,805,965.04
    支付的各项税费                               22,162,923.22                    31,007,462.08
    支付其他与经营活动有关的现金                848,741,390.27                   602,450,563.13
经营活动现金流出小计                            939,776,996.04                   673,837,212.15
经营活动产生的现金流量净额                      306,189,693.81                   180,671,039.55
二、投资活动产生的现金流量:
    收回投资收到的现金                         1,602,600,000.00              1,080,010,000.00
    取得投资收益收到的现金                       29,966,134.26                   126,340,343.52
    处置固定资产、无形资产和其他长期资
                                                                                      99,500.00
产收回的现金净额
    处置子公司及其他营业单位收到的现
金净额
    收到其他与投资活动有关的现金
投资活动现金流入小计                           1,632,566,134.26              1,206,449,843.52
    购建固定资产、无形资产和其他长期资
                                                     4,618,659.49                 10,233,033.81
产支付的现金
    投资支付的现金                             1,602,600,000.00              1,080,010,000.00
    取得子公司及其他营业单位支付的现
                                                407,632,700.00               1,049,367,200.00
金净额
    支付其他与投资活动有关的现金                                                     840,000.00
投资活动现金流出小计                           2,014,851,359.49              2,140,450,233.81
投资活动产生的现金流量净额                     -382,285,225.23                   -934,000,390.29
三、筹资活动产生的现金流量:
    吸收投资收到的现金
    取得借款收到的现金                          800,000,000.00                   750,000,000.00
    发行债券收到的现金
    收到其他与筹资活动有关的现金                             0.00
筹资活动现金流入小计                            800,000,000.00                   750,000,000.00
    偿还债务支付的现金                          700,000,000.00                   480,000,000.00
    分配股利、利润或偿付利息支付的现金           17,211,944.46                    12,800,333.33
    支付其他与筹资活动有关的现金
筹资活动现金流出小计                            717,211,944.46                   492,800,333.33
筹资活动产生的现金流量净额                       82,788,055.54                   257,199,666.67


                                          第 19 页
  哈尔滨誉衡药业股份有限公司


四、汇率变动对现金及现金等价物的影响
五、现金及现金等价物净增加额                                6,692,524.12              -496,129,684.07
    加:期初现金及现金等价物余额                       261,982,833.79                  605,448,454.91
六、期末现金及现金等价物余额                           268,675,357.91                  109,318,770.84

法定代表人:朱吉满                     主管会计工作负责人:刁秀强           会计机构负责人:程朝阳



                                                                           哈尔滨誉衡药业股份有限公司

                                                                                  法定代表人:朱吉满

                                                                               二〇一六年四月二十七日




                                                 第 20 页